Takeda has bolstered its near-term pipeline ... Drug treatments are also used to treat the disease, but the standard first-line therapies of hydroxyurea or interferons are not particularly ...
Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals ... around 115 million people in the US, and standard therapy is eradication with a combination ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...
Rio Takeda shot a blistering 8-under 64 to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia.
Hosted on MSN1mon
Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEOTakeda Pharmaceutical named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but growing ranks of women leading Japanese companies ...
It's never finished but I think we have made great steps forward. Insider: You mention the Shire acquisition. How important has that been for Takeda's global transformation journey? Related ...
SANYA, China (AP) — Rio Takeda of Japan shot a 3-under 69 on Saturday to hold a two-shot lead after three rounds of the LPGA's Blue Bay tournament on China's southern island of Hainan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback